HNRNPA2B1 and breast cancer: In BC, downregulation of the reader HNRNPA2B1 can reduce BC cell proliferation, increase autophagic flux, and partially abrogate resistance to olaparib, potentially becoming an important target for increasing chemotherapy sensitivity [75].